Date: 2015-09-21
Type of information: Services contract
Compound: BIO101 (Stemmacantha carthamoides)
Company: Biophytis (France) Patheon (USA - NC)
Therapeutic area: Metabolic diseases
Type agreement: services contract production manufacturing
Action mechanism:
Disease: sarcopenic obesity
Details: * On September 21, 2015, Biophytis, a biotech company specialized in the development of drug candidates to treat aging diseases, announced that it has entered into an agreement for the production of clinical batches of BIO101 with Patheon, a U.S Contract Manufacturing Organization (CMO). This contract is a significant step in the ongoing phase 2b trial with BIO101 in the sarcopenic obesity. The drug candidate BIO101 is a product (Stemmacantha carthamoides) that presents several favorable properties on muscle cells : it stimulates protein synthesis (hepatocytes, myocytes) and reveals hypoglycemiant and hypolipemiant effects. Within the framework of this partnership, Patheon will handle the manufacturing of the clinical batches of BIO101. These batches will be used by Biophytis for the phase 2b test which will be launched in Europe soon after obtaining authorization from the regulatory authorities. This clinical trial will be the first one in the world to treat sarcopenic obese patients.
Financial terms:
Latest news:
